(2-Aminomethyl-bicyclo[3.1.0]hex-2-yl)-acetic acid | 444088-06-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2-Aminomethyl-bicyclo[3.1.0]hex-2-yl)-acetic acid
• 英文别名: 2-[2-(Aminomethyl)-2-bicyclo[3.1.0]hexanyl]acetic acid
• CAS: 444088-06-6
• 化学式: C₉H₁₅NO₂
• 分子量: 169.224
• InChiKey: LEKQUDBVQFBMTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• PHARMACEUTICAL USES FOR ALPHA2DELTA LIGANDS
  申请人：Dooley James David

  公开号：US20070213401A1

  公开（公告）日：2007-09-13

  The invention relates to a method of treating central nervous system disorders and other disorders by administering an alpha2delta ligand such as, for example, a compound of the formula or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen or straight or branched lower alkyl, and n is an integer of from 4 to 6.

  该发明涉及一种通过给予α2δ配体来治疗中枢神经系统疾病和其他疾病的方法，例如给予公式中的化合物或其药学上可接受的盐，其中R1为氢或直链或支链低碳基，n为4到6的整数。
• Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists
  申请人：Audoly Laurent Pascal

  公开号：US20090036495A1

  公开（公告）日：2009-02-05

  The instant invention relates to a combination of an EP4-receptor antagonist and an alpha-2-delta ligand, and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly inflammatory, neuropathic, visceral and nociceptive pain.

  本发明涉及一种EP4受体拮抗剂和α-2-δ配体的组合物，及其药学上可接受的盐、制药组合物及其在治疗疼痛，特别是炎症性、神经病理性、内脏性和伤害性疼痛中的用途。
• COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS
  申请人：Dooley David James

  公开号：US20100081718A1

  公开（公告）日：2010-04-01

  The instant invention relates to a combination, particularly a synergistic combination, of an alpha-2-delta ligand and a dual serotonin-noradrenaline re-uptake inhibitor (DSNRI) or one or both of a selective serotonin re-uptake inhibitor (SSRI) and a selective noradrenaline re-uptake inhibitor (SNRI), and pharmaceutically acceptable salths thereof, pharmaceutical compositions thereof and their use in the treatment of pain, particularly neuropathic pain.

  本发明涉及一种组合物，特别是一种协同作用的组合物，包括α-2-δ配体和双重血清素-去甲肾上腺素再摄取抑制剂（DSNRI）或选择性血清素再摄取抑制剂（SSRI）和/或选择性去甲肾上腺素再摄取抑制剂（SNRI）中的一种或两种，以及其药学上可接受的盐、药物组成物和在治疗疼痛，特别是神经病理性疼痛中的应用。
• Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
  申请人：OMEROS CORPORATION

  公开号：US20130267502A1

  公开（公告）日：2013-10-10

  This disclosure is directed to treatment of addictions and primary impulse-control disorders using phosphodiesterase 7 (PDE7) inhibitors, alone or in combination with other therapeutic agents.

  本公开涉及使用磷酸二酯酶7（PDE7）抑制剂，单独或与其他治疗药物联合治疗成瘾和原发性冲动控制障碍。
• Use of PDE7 Inhibitors for the Treatment of Movement Disorders
  申请人：OMEROS CORPORATION

  公开号：US20140179717A1

  公开（公告）日：2014-06-26

  A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.

  一种治疗神经运动障碍病理学相关的运动异常的方法，例如帕金森病或不宁腿综合症，通过给予治疗有效量的PDE7抑制剂。该发明的一个方面是在给予多巴胺激动剂或前体（如左旋多巴）的同时给予PDE7抑制剂。在该发明的另一个方面，PDE7抑制剂可以相对于其他分子靶点（i）已知与帕金森病的病理学有关或（ii）其他治疗帕金森病有效的药物作用的靶点而选择性地作用于PDE7。